Family Medicine · Jackson, TN
NPI
1396837852
Since 2006
Specialty
Family Medicine
Code 207Q00000X
Group practices
0
Medicare group memberships
Hospitals
1
Hospital affiliations
2815 N Highland Ave, Suite C
Jackson, TN, 38305
Phone (731) 660-6055
Medicare paid, 2024
$69K
1,591 services
Medicare patients, 2024
110
Average age 69
Drug cost, 2024
$1.2M
14,813 prescriptions
Company payments, 2025
$462
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Earl L Stewart was code 99214 (office e&m - established), 516 times for 101 patients. In total Earl L Stewart billed 1,591 services in 16 codes, and Medicare paid $69K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 516 | 101 | $76.38 | $39K |
| 99213 Office E&M - Established | Office | 371 | 88 | $55.25 | $20K |
| 96372 Injection Administration | Office | 191 | 61 | $9.05 | $1,729 |
| 81002 Clinical Chemistry | Office | 147 | 79 | $3.41 | $501 |
| 99442 Telephone Services | Office | 79 | 31 | $62.18 | $4,912 |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 75 | 30 | $0.50 | $37.79 |
| 82274 Immunoassay | Office | 60 | 51 | $15.60 | $936 |
| J0696 Injection, ceftriaxone sodium, per 250 mg | Office | 60 | 26 | $0.31 | $18.43 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 45 | 27 | $0.53 | $23.94 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 13 | 12 | $0.08 | $0.99 |
By year: 2022 $71K for 1,713 services; 2023 $73K for 1,718 services; 2024 $69K for 1,591 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81002 Clinical Chemistry | 147 | 79 | $3.41 | $501 |
| 82274 Immunoassay | 60 | 51 | $15.60 | $936 |
Medicare prescription drug claims, 2024
In 2024, the drug Earl L Stewart prescribed most often to Medicare patients was Rosuvastatin Calcium, with 800 prescriptions and refills. In total Earl L Stewart wrote 14,813 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rosuvastatin Calcium Generic | 800 | 1,822 | 221 | $8,225 |
| Amlodipine Besylate Generic | 554 | 1,267 | 135 | $2,652 |
| Atorvastatin Calcium Generic | 424 | 862 | 106 | $4,360 |
| Tizanidine Hcl Generic | 414 | 450 | 174 | $3,811 |
| Furosemide Generic | 314 | 672 | 102 | $1,484 |
| Hydralazine Hcl Generic | 295 | 728 | 90 | $3,789 |
| Gabapentin Generic | 275 | 275 | 60 | $3,371 |
| Famotidine Generic | 256 | 491 | 77 | $3,972 |
| Fluticasone Propionate Generic | 252 | 317 | 93 | $4,591 |
| Cephalexin Generic | 231 | 231 | 152 | $1,632 |
| Nateglinide Generic | 231 | 490 | 65 | $21K |
| Metformin Hcl Generic | 230 | 533 | 74 | $937 |
| Levothyroxine Sodium Generic | 217 | 471 | 46 | $2,419 |
| Omeprazole Generic | 208 | 355 | 55 | $2,734 |
| Potassium Chloride Generic | 207 | 484 | 71 | $2,526 |
Brand drugs: 1,611 claims; generic drugs: 13,063 claims; opioid claims: 35.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Earl L Stewart $462 ($462 in general payments such as food, travel and fees) from 11 companies. The largest payer was Abbvie Inc. with $162.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 5 | $162 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $70.96 |
| Lilly USA, LLC LLY | 2 | $66.37 |
| ACADIA Pharmaceuticals Inc ACAD | 1 | $30.7 |
| GlaxoSmithKline, LLC. GSK | 1 | $26.22 |
| Ardelyx, Inc. ARDX | 1 | $23.64 |
| Abbott Laboratories ABT | 1 | $20.57 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $17.21 |
| Cipher Pharmaceuticals US LLC CPH.TO | 1 | $16.7 |
| Novo Nordisk Inc NVO | 1 | $13.78 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.